Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01869829
Other study ID # Pro00045657
Secondary ID 1R01AI103315-01A
Status Completed
Phase
First received
Last updated
Start date January 2015
Est. completion date April 2018

Study information

Verified date January 2022
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The overarching objective is to develop new evidence-based treatment guidelines for invasive fungal diseases in children. To accomplish that, this protocol will focus on two specific aims: 1) Compare the effectiveness of echinocandin versus amphotericin B or triazole antifungal therapy for pediatric invasive candidiasis and for the subset of patients with invasive candidemia; 2) Characterize the incidence rate of inpatient pediatric invasive candidiasis per hospital admissions.


Description:

This study is a multicenter, national and international, prospective observational comparative effectiveness study. The primary aim of this study is to compare the effectiveness of echinocandin versus amphotericin B or triazole antifungal therapy for pediatric invasive candidiasis and for invasive candidemia. The primary effectiveness endpoint for study aim 1 is the comparison of global response at 14 days of antifungal therapy between antifungal therapeutic classes. The secondary effectiveness endpoints for study aim 1 are comparative effectiveness of the 1) global response to antifungal therapy after 30 days and 2) all-cause mortality at 30 days. The secondary aim is to characterize the frequency of pediatric candidiasis by describing the incidence of pediatric candidiasis relative to all pediatric admissions. For this aim, the investigators will use descriptive statistics to establish the frequency of hospital admissions involving an invasive candidiasis per total hospital admissions and total hospital days during the study period.


Recruitment information / eligibility

Status Completed
Enrollment 750
Est. completion date April 2018
Est. primary completion date April 2018
Accepts healthy volunteers No
Gender All
Age group 120 Days to 18 Years
Eligibility Inclusion Criteria: 1. Males or females age > 120 days and <18 years 2. Documented proven or probable case of invasive candidiasis 3. Parental/guardian permission (informed consent, if required) and if appropriate, child assent (if required). Exclusion Criteria: 1) Any history of prior Candida infection within the previous 35 days (These patients will not be eligible for analysis in aim 1 but will be eligible for inclusion of aim 2)

Study Design


Intervention

Drug:
Observational antifungal therapy
Observational study of primary antifungal therapy utilized and outcomes, including: fluconazole, voriconazole, amphotericin B, caspofungin, and micafungin All agents are given as standard of care.

Locations

Country Name City State
Canada The Hospital for Sick Children Toronto
Colombia Centro de Estudios en Infectologia Pediatricia Cali
Colombia Centro Medico Imbanaco Cali
Greece 3rd Department Pediatrics Aristole University School of Medicine, Hippokration Hospital Thessaloniki
India Postgraduate Institute of Medical Education and Research Chandigarh
Italy Instuto Giannina Gaslini Genoa
Saudi Arabia King Faisal Specialist Hospital & Research Center Riyadh
Spain Hospital d'Universitari Vall d'Hebron Barcelona
United States Mott Children's Hospital Ann Arbor Michigan
United States Children's Hospital Colorado Aurora Colorado
United States Dell Children's Medical Center Austin Texas
United States Boston Children's Hospital Boston Massachusetts
United States Ann and Robert Lurie Children's Hospital of Chicago Chicago Illinois
United States Cincinnati Children's Medical Center Cincinnati Ohio
United States Cleveland Clinic Children's Cleveland Ohio
United States Duke University Durham North Carolina
United States Texas Children's Hospital Houston Texas
United States Children's Mercy Kansas City Missouri
United States Arkansas Children's Hospital Little Rock Arkansas
United States St. Jude Children's Research Hospital Memphis Tennessee
United States Medical College of Wisconsin Milwaukee Wisconsin
United States Children's Hospital and Clinics of Minnesota Minneapolis Minnesota
United States Monroe Carell Jr. Children's Hospital at Vanderbilt Nashville Tennessee
United States Cohen Children's Medical Center of New York New Hyde Park New York
United States New York Presbyterian Phyllis and David Komansky Center for Children's Health New York New York
United States Children's Hospital of Orange County Orange California
United States Lucile Packard Children's Hospital at Stanford Palo Alto California
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States Children's Hospital of Pittsburgh Pittsburgh Pennsylvania
United States OHSU Doernbecher Children's Hospital Portland Oregon
United States All Children's Hospital Saint Petersburg Florida
United States Rady Children's Hospital San Diego California
United States UCSF Benioff Children's Hospital San Francisco California
United States Seattle Children's Seattle Washington
United States Children's National Medical Center Washington District of Columbia

Sponsors (3)

Lead Sponsor Collaborator
Duke University Children's Hospital of Philadelphia, National Institute of Allergy and Infectious Diseases (NIAID)

Countries where clinical trial is conducted

United States,  Canada,  Colombia,  Greece,  India,  Italy,  Saudi Arabia,  Spain, 

References & Publications (1)

Fisher BT, Zaoutis TE, Xiao R, Wattier RL, Castagnola E, Pana ZD, Fullenkamp A, Boge CLK, Ross RK, Yildirim I, Palazzi DL, Danziger-Isakov L, Vora SB, Arrieta A, Yin DE, Avilés-Robles M, Sharma T, Tribble AC, Maron G, Berman D, Green M, Sung L, Romero J, — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Incidence of pediatric invasive fungal infections 4 years
Primary Global response to antifungal therapy 14 days
Secondary Global response of antifungal therapy 30 days
Secondary All-cause mortality 30 days